Press Release

TFF Pharmaceuticals to Meet with Investors and Commercial Partners in San Francisco during the JP Morgan Healthcare Conference

December 11, 2019 at 8:00 AM EST

AUSTIN, Texas--(BUSINESS WIRE)--Dec. 11, 2019-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will be meeting with investors and commercial partners from January 13 to January 16, 2020 in San Francisco, concurrent with the JP Morgan Healthcare Conference and 2020 Biotech Showcase.

TFF Pharmaceuticals recently completed a $24 million initial public offering, and on November 25th, initiated a Phase 1 clinical trial of its unique Voriconazole Inhalation Powder that is being investigated for the treatment of a severe and life-threatening disease: Invasive Pulmonary Aspergillosis, or IPA. This has the potential to be the first dry powder inhaled fungicide on the market. The Company’s second candidate, TFF Tacrolimus Inhalation Powder, is an inhaled dry powder version of tacrolimus, one of the most commonly administered immunosuppressive drug used in solid organ transplants. An IND for TFF Tacrolimus Inhalation Powder is expected to be filed in Q1-2020 and will be developed for the prevention of organ rejection in patients receiving lung transplants.

TFF Pharmaceuticals senior management will be available to meet at the LaVoieHealthScience Corporate Access suites at the San Francisco Marriott Marquis and the Hotel Spero.

For Investor meetings, please contact Paul Sagan at psagan@lavoiehealthscience.com, 617-374-8800 x112

For Partnering/Business Development meetings, please contact Chris Cano at ccano@tffpharma.com, 609-933-3938

About TFF Pharmaceuticals’ Thin Film Freezing technology platform

TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.

SAFE HARBOR

This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFF platform and its dry powder version of Voriconazole and Tacrolimus, and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform and (iii) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the on December 9, 2019. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Source: TFF Pharmaceuticals, Inc.

Company Contacts:
Glenn Mattes President and CEO TFF Pharmaceuticals, Inc gmattes@tffpharma.com 737-802-1973
Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc. kcoleman@tffpharma.com 817-989-6358

Investor Relations and Media Contact:
Paul Sagan
LaVoieHealthScience
psagan@lavoiehealthscience.com
617-953-4779

Top